Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus Ankara
Author(s) -
Eric Sandström,
Charlotta Nilsson,
Bo Hejdeman,
Andreas Bråve,
Göran Bratt,
Merlin L. Robb,
Josephine H. Cox,
Thomas C. VanCott,
Mary Marovich,
Richard Stout,
Said Aboud,
Muhammad Bakari,
Kisali Pallangyo,
Karl Ljungberg,
Bernard Moss,
Patricia L. Earl,
Nelson L. Michael,
Deborah L. Birx,
Fred Mhalu,
Britta Wahrén,
Gunnel Biberfeld
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/592507
Subject(s) - immunogenicity , virology , vaccinia , modified vaccinia ankara , poxviridae , heterologous , dna vaccination , virus , hiv vaccine , orthopoxvirus , biology , duck embryo vaccine , aids vaccines , medicine , recombinant dna , human immunodeficiency virus (hiv) , vaccine trial , immunology , antibody , immunization , gene , genetics , rabies virus
A human immunodeficiency virus (HIV) vaccine that limits disease and transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an HIV vaccine that combines a plasmid-DNA priming vaccine and a modified vaccinia virus Ankara (MVA) boosting vaccine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom